Court upholds suspension of generic Plavix sales

Share this article:
A federal appeals court upheld an injunction putting a halt to Apotex’s sale of a generic version of the blockbuster heart drug Plavix, The Wall Street Journal reported. The US Court of Appeals for the Federal Circuit in Washington upheld an August injunction issued by the US District Court in Manhattan. The ruling marks a legal victory for Bristol-Myers Squibb and Sanofi-Aventis, marketers of Plavix. The appellate court ruling means that Canadian generics company Apotex may not resume selling a cheaper copycat version of Plavix in the US, pending the outcome of a patent rights trial set to begin in January. Apotex began selling generic Plavix in August despite the existence of a Sanofi US patent for Plavix that doesn’t expire until 2011. Apotex argued that the patent is invalid and unenforceable, a contention disputed by Bristol-Myers and Sanofi.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.